Sort
48,018 grants matching “immunotherapy”
Understanding and Mitigating Vascular Side-Effects Associated with Anti-Amyloid Immunotherapy
$831,601Cynthia A Lemere · Brigham And Women'S Hospital · R01 · FY2024 · NS
Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy
$831,128Nolan Sigal · Tunitas Therapeutics, Inc. · R42 · FY2013 · AI
Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes
$831,071Michael S Kuhns · University Of Arizona · R01 · FY2023 · DK
Development of FISH Molecular Diagnostics to support Clinical Trials at NCI
$830,915Svetlana Pack · Division Of Basic Sciences - Nci · ZID · FY2011 · CA
Leadership, Planning, and Evaluation
$830,797Ramesh A Shivdasani · Dana-Farber Cancer Inst · P30 · FY2023 · CA
Leadership, Planning, and Evaluation
$830,727Ramesh A Shivdasani · Dana-Farber Cancer Inst · P30 · FY2022 · CA
High Density Cell Respirator (HDCR) for the production of vectors, viruses and vaccines
$830,585Nicole Bergman · Xdemics Corporation · R42 · FY2022 · TR
Children's Oncology Group Statistics and Data Center
$830,139Todd A Alonzo · Public Health Institute · U10 · FY2020 · CA
Recombinant Interleukin-12 for Cutaneous T-Cell Lymphoma
$829,822University Of Pennsylvania · R01 · FY2004 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
$829,650Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2020 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
$829,650Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2018 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
$829,650Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2019 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
$829,650Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2022 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
$829,650Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2021 · CA
Regulation of CTCF Functions and Target Sites by Cancer/Testis-specific CTCF Like BORIS Factor
$829,516Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Cancer Imaging and Therapy Analysis Platform (CITAP)
$829,202Madhusudhana Gargesha · Bioinvision, Inc. · R44 · FY2019 · CA
Advancing Cancer Therapy through Groundbreaking Research in Radiation Biology
$829,136David G Kirsch · Roswell Park Cancer Institute Corp · R35 · FY2025 · CA
Attenuating Inflammation to Restore GI Tract Integrity and Reduce Viral Reservoirs During cART
$829,058Jacob D Estes · Oregon Health & Science University · R01 · FY2018 · DK
Building better T cell receptors for targeted immunotherapy
$828,987Brian M Baker · University Of Notre Dame · R01 · FY2019 · AI
The Role of Food Sensitization in Cardiovascular Disease
$828,775Corinne Keet · Univ Of North Carolina Chapel Hill · R01 · FY2024 · AI
Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes
$828,648Michael S Kuhns · University Of Arizona · R01 · FY2024 · DK
TARGETING THE TUMOR MICROENVIRONMENT TO ENHANCE IMMUNOTHERAPY FOR SCLC
$828,591Duke University · · FY2025 · Defense Health Agency
NY-ESO-1-SPECIFIC TCR-ENGINEERED T CELL IMMUNOTHERAPY FOR TRIPLE NEGATIVE BREAST CANCER
$828,577The Methodist Hospital Research Institute · · FY2016 · Defense Health Agency
Developmental Funds
$828,396Ben H Park · Vanderbilt University Medical Center · P30 · FY2023 · CA
Developmental Funds
$828,396Ben H Park · Vanderbilt University Medical Center · P30 · FY2022 · CA